Navigation Links
Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors
Date:8/15/2011

ST. LOUIS, MO, August 15, 2011A compound found in green tea shows great promise for the development of drugs to treat two types of tumors and a deadly congenital disease. The discovery is the result of research led by Principal Investigator, Dr. Thomas Smith at The Donald Danforth Plant Science Center and his colleagues at The Children's Hospital of Philadelphia. Their findings are published in the recent article, "Green Tea Polyphenols Control Dysregulated Glutamate Dehydrogenase In Transgenic Mice By Hijacking The ADP Activation Site" in The Journal of Biological Chemistry.

Glutamate dehydrogenase (GDH) is found in all living organisms and is responsible for the digestion of amino acids. In animals, GDH is controlled by a complex network of metabolites. For decades it was not clear why animals required such regulation but other kingdoms did not. This was partially answered by the Stanley group's finding that a deadly congenital disease, hyperinsulinism/hyperammonemia (HHS), is caused by the loss of some of this regulation. In this disorder, patients (typically children) respond to the consumption of protein by over secreting insulin, becoming severely hypoglycemic, often leading to death.

Using atomic structures to understand the differences between animals and plants, Dr. Smith and his colleagues discovered that two compounds found naturally in green tea are able to compensate for this genetic disorder by turning off GDH in isolated and when the green tea compounds were administered orally. The Smith lab also used X-ray crystallography to determine the atomic structure of these green tea compounds bound to the enzyme. With this atomic information, they hope to be able to modify these natural compounds to design and develop better drugs.

Interestingly, two other research groups have validated and extended these findings to demonstrate that blocking GDH with green tea is very effective at killing two different kinds of tumors; glioblastomas, an aggressive type of brain tumor, and tuberous sclerosis complex disorder, a genetic disease that causes non-malignant tumors to grow on a number of organs.

"While these compounds from green tea are extremely safe and consumed by millions every day, they have a number of properties that make them difficult to use as actual drugs. Nevertheless, our ongoing collaboration with the Stanley lab shows that there are natural compounds from plants that can control this deadly disorder and, with the atomic structure in hand, can be used as a starting point for further drug design."


'/>"/>

Contact: Melanie Bernds
mbernds@danforthcenter.org
314-587-1647
Donald Danforth Plant Science Center
Source:Eurekalert  

Related biology news :

1. Researchers discover freshwater mussel species thought to be extinct
2. NYU Langone researchers identify a signaling pathway as possible target for cancer treatment
3. Toronto researchers first to discover new genetic clue in the development of rheumatoid arthritis
4. Researchers decode workings of mysterious, but critical TB drug
5. Researchers fight cholera with computer forecasting
6. Vanderbilt researchers, international team, uncover genes linked to multiple sclerosis
7. Narcissism may benefit the young, researchers report; but older adults? Not so much
8. York U researchers zero in on protein that may help treat obesity, diabetes
9. Researchers use human cells to engineer functional anal sphincters in lab
10. Researchers use neutrons to spy on the elusive hydronium ion
11. UGA researchers study threats to white sturgeon
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new study published in ... previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute ... of blood sampling may improve the value of a blood-based test.” The study ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
Breaking Biology Technology: